NOV 08, 2017 12:00 PM PST
Combined immunohistochemistry and RNA in situ hybridization to elucidate tumor molecular heterogeneity in prostate cancer
Presented at the Clinical Diagnostics & Research 2017 Virtual Event
SPONSORED BY: Advanced Cell Diagnostics
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE | Florida CE
1 4 100

Speakers:
  • Associate Scientist, Henry Ford Health System
    Biography
      Dr. Palanisamy completed his undergraduate and graduate studies at the University of Madras, India, and is currently an Associate/Senior Scientist at the Henry Ford Health System. He also holds an adjunct faculty appointment with the Michigan Center for Translational Pathology (MCTP) at the University of Michigan. His current research program is focused on the discovery of cancer biomarkers in lymphomas and solid cancers. During his post-doctoral research at the Memorial Sloan-Kettering Cancer Center, Dr. Palanisamy's work contributed to the discovery of recurrent gene fusions in follicular and diffuse large B-cell lymphomas. He was the founding Director of Research and Development at the Cancer Genetics, Inc (CGIX), where he introduced novel approaches to develop diagnostic reagents targeting chromosomal translocations in cancer. Dr. Palanisamy pioneered the application of next generation sequencing technology for transcriptome sequencing and discovered novel "druggable" gene fusions in prostate cancer, gastric cancer, and melanoma (Palanisamy et al., Nat Med 2010). His current research aims to understand the molecular basis of tumor heterogeneity in solid cancers, with particular focus on prostate cancer, and its impact in early diagnosis, response to treatment, and clinical outcome.

    Abstract:

    Currently, prostate cancer is the second leading cause of death from cancer in North America, the most frequent malignancy in men from all ethnicities, surpassing lung cancer. Prostate tumors are highly heterogeneous and there are many studies evaluating the molecular profile or ‘fingerprint’ of prostate cancer.  Conventional analysis reviews the protein expression of key markers via serum analysis and immunohistochemistry (IHC) of the biopsy.  In this presentation we will review how RNA in situ hybridization (ISH) analysis of prostate cancer can unravel the molecular heterogeneity of the tumor, identify molecular subsets and detect key fusions and mutations of the RNA.  We will also present a comparison of IHC and ISH technology and the combination of dual color IHC and dual color ISH can be used to enhance simultaneous evaluation of DNA, RNA and protein, revealing the molecular profile of prostate cancer.


    Show Resources
    Loading Comments...